Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Logothetis

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Urology|September 1, 1994
Phase II trial of low dose gamma-interferon in metastatic renal cell carcinomaJ A Ellerhorst, R G Kilbourn, R J Amato, et al.
Anticancer Research|May 1, 1994
5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimenC J Logothetis, E Hossan, G Recondo, et al.
Cancer Biotherapy|January 1, 1995
Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancerA Sella, B B Aggarwal, R G Kilbourn, et al.
The Journal of Urology|June 1, 1988
Adjuvant chemotherapy of bladder cancer: a preliminary reportC J Logothetis, D E Johnson, C Chong, et al.
Urologic Oncology|January 13, 2011
A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignanciesS M Tu, E D Robinson, R J Amato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancerC J Logothetis, K K Wu, L D Finn, et al.
Cancer Gene Therapy|July 27, 1999
Tumor-suppressive activity of CD66a in prostate cancerW Luo, M Tapolsky, K Earley, et al.
Annals of Clinical and Laboratory Science|November 1, 1996
Serum calcitonin in small cell carcinoma of the prostateS J Sim, A B Glassman, J Y Ro, et al.
Urologic Oncology|January 13, 2011
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancerJ T Hsieh, H C Wu, Y Wang, et al.
The Journal of Urology|January 1, 1989
Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experienceC J Logothetis, F H Dexeus, C Chong, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Urology|September 1, 1994
Phase II trial of low dose gamma-interferon in metastatic renal cell carcinomaJ A Ellerhorst, R G Kilbourn, R J Amato, et al.
Anticancer Research|May 1, 1994
5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimenC J Logothetis, E Hossan, G Recondo, et al.
Cancer Biotherapy|January 1, 1995
Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancerA Sella, B B Aggarwal, R G Kilbourn, et al.
The Journal of Urology|June 1, 1988
Adjuvant chemotherapy of bladder cancer: a preliminary reportC J Logothetis, D E Johnson, C Chong, et al.
Urologic Oncology|January 13, 2011
A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignanciesS M Tu, E D Robinson, R J Amato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancerC J Logothetis, K K Wu, L D Finn, et al.
Cancer Gene Therapy|July 27, 1999
Tumor-suppressive activity of CD66a in prostate cancerW Luo, M Tapolsky, K Earley, et al.
Annals of Clinical and Laboratory Science|November 1, 1996
Serum calcitonin in small cell carcinoma of the prostateS J Sim, A B Glassman, J Y Ro, et al.
Urologic Oncology|January 13, 2011
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancerJ T Hsieh, H C Wu, Y Wang, et al.
The Journal of Urology|January 1, 1989
Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experienceC J Logothetis, F H Dexeus, C Chong, et al.
Pageof 15